Stock Market Reviews

RCKT (Rocket Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on RCKT (Rocket Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
  CRANBURY, N.J., November 06, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025.
  Nov 6, 2025 - $RCKT
• Rocket Pharmaceuticals: Q3 Earnings Snapshot
  CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. RCKT) on Thursday reported a loss of $50.3 million in its third quarter. The Cranbury, New Jersey-based company said it had a loss of 45 cents per share.
  Nov 6, 2025 - $RCKT
• Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now?
  Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best NASDAQ stocks under $5 to buy now. On October 14, Rocket Pharmaceuticals announced that the US FDA accepted the resubmission of the Biologics License Application/BLA for KRESLADI (marnetegragene autotemcel; marne-cel). KRESLADI is a lentiviral vector/LV-based investigational gene therapy intended for the treatment of severe Leukocyte Adhesion […]
  Oct 26, 2025 - $RCKT
• RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
  Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
  Oct 15, 2025 - $RCKT
• Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
  CRANBURY, N.J., October 14, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte
  Oct 14, 2025 - $RCKT
• Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  CRANBURY, N.J., October 10, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that on October 6, 2025, the Compensation Committee of Rocket’s Board of Directors approved the grant of inducement equity incentive awards to its newly-hired Chief Medical Officer, Dr. Syed Rizvi.
  Oct 10, 2025 - $RCKT
• Rocket ditches blood disorder gene therapy in ongoing pipeline pivot
  Rocket has pulled an approval application to the FDA, with the biotech considering offloading the asset via external partnerships.
  Oct 3, 2025 - $RCKT
• Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation
  Just because a business does not make any money, does not mean that the stock will go down. For example, although...
  Sep 23, 2025 - $RCKT
• Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
  CRANBURY, N.J., August 28, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 2025 Cantor Fitzgerald Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
  Aug 28, 2025 - $RCKT
• Rocket to relaunch rare disease trial after FDA approval
  The Phase II trial, which was placed on hold due to a patient death, will now resume with a reduced dose and altered regimen.
  Aug 21, 2025 - $RCKT